Drug Profile
Research programme: monoclonal antibodies - Trellis Bioscience
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Trellis Bioscience
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Cytomegalovirus infections; Methicillin-resistant Staphylococcus aureus infections; Respiratory syncytial virus infections; Streptococcal infections
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (Parenteral)